Kaken

How early-stage clinical research is facilitating the new wave of personalised medicines

is also being used to treat autoimmune and cardiac conditions, and biologic medicines, which now account for 15% of medicines prescribed in Japan and 30% in the USA (in 2018).

Piloting a route to the biosimilars opportunities in Europe

Japan is also taking a proactive interest in the field. The hope is that respective national and regional regulators will choose to increasingly share best practice rather than reinvent the wheel

Novo Nordisk partners with Heartseed on heart failure cell therapy

However, Novo Nordisk has the rights to co-commercialise HS-001 with Heartseed in Japan, with equal profit and cost sharing. ... The Japanese biotech company is also eligible to receive tiered high single-digit to low double-digit royalties of annual net

BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer

As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront

AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate

Both companies will jointly develop and commercialise datopotamab deruxtecan worldwide, apart from in Japan where Daiichi will retain exclusive rights.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]